Outsourced Pharma Webinars

  1. Rapid Developability Assessment Of Early Phase Molecules: Parallel Screening Of Enabling Technologies And Use Of PBPK Modeling 5/19/2020

    Scaling-up liquid formulations can present a number of challenges and headaches. This is especially true for complex solutions, suspensions and emulsions as well as biologics, sterile products, potent compounds and sensitive APIs. In this webcast, learn about potential formulation and filling issues when transitioning a liquid formulation from feasibility through commercialization.

  2. Complex Liquid Formulations: Solutions For Scale-Up Challenges 5/19/2020

    Scaling-up liquid formulations can present a number of challenges and headaches. In this webinar product development experts share insights on a variety of formulation issues including mixing, solubility, microfluidization, viscosity, filtration and special API handling, with discussed solutions based on Catalent’s expertise in complex formulation.

  3. Sources, Effects, And The Importance Of Elemental Impurities For Finished Drug Products 5/19/2020

    Elemental impurities can arise from a variety of sources, such as active pharmaceutical ingredients (API), excipients, manufacturing equipment, and primary container closure systems.  ICH Q3D recommends that manufacturers conduct a product risk assessment by identifying and assessing known and potential sources of elemental impurities.  This webinar reviews the impact of the most recent regulatory changes related to elemental impurities testing, guidance on the best routes to compliance, and an overview of the elemental impurities risk assessment process.

  4. Coating: Curing Your Complex Oral Solid Dose Challenges 5/15/2020

    Pfizer CentreOne’s oral solid dose experts discuss how advances in the mathematics and engineering involved in understanding the process can tackle these challenges and ensure functional coating and drug layering continue to be a viable solution for the next generation of OSD drug products. Discover how coatings expertise could transform your OSD drug.

  5. Expanding SPR Uses In Antibody Effector Function Determination 2/25/2020

    To minimize risk and to get “true” affinity in binding analysis, we've adopted the latest innovation in surface plasmon resonance technology to develop and qualify assays for mAbs and other therapeutic proteins.

  6. Novel Analytics To Improve Bioprocessing And Validation Guideline Review 2/25/2020

    This presentation highlights how innovative protein analysis technologies have been adopted for better comparability, release testing, and impurity monitoring, to improve characterization and productivity.

  7. Insights in Pharmaceutical Manufacturing, Clinical Research and Technology 2/13/2020

    ISR conducted approximately two dozen pieces of research for syndication in 2019. This summary highlights learnings from these projects, and provides real, usable data for 2020 activities.

  8. Reduce Product Variability, Control Temp Rates To Improve Cell Therapies 2/4/2020

    Reduced input variables and careful freeze/thaw cycles are critical in T cell processing. Here, experts examine how these factors influence and optimize mononuclear cell enrichment and cryopreservation.

  9. Principles Of Immunogenicity Assessment Using Biacore T200 SPR System 2/4/2020

    Usually, ligand binding technologies such as ELISA are used for early immune responses, whereas SPR technology is utilized for the characterization of antibody isotypes.

  10. Process Characterization: Ready For The FDA? (Webinar) 1/31/2020

    In this webinar, Greg Sears, Ph.D, Global Director, Process Characterization, Head of Manufacturing Science and Technology, Pharma Services, Biologics at Thermo Fisher Scientific, discusses process characterization basics, including information on what’s optional vs. what’s required.